Local heterogeneity in Lassa fever serology in rural Nigeria: Implications for vaccine trial site selection
David Simons, Christina Harden, Natalie Imirzian, Katharine E. T. Thompson, Nzube Michael Ifebueme, Sunday Eziechina, Helen Ignatius, Diana Marcus, Fisayomi Aderibigbe, James T. Koninga, Martin Meremikwu, Lina Moses, David W. Redding, Sagan Friant, David Safronetz, David Safronetz, David Safronetz, · 2026
Read Local heterogeneity in Lassa fever serology in rural Nigeria: Implications for vaccine trial site selection by David Simons, Christina Harden, Natalie Imirzian, Katharine E. T. Thompson, Nzube Michael Ifebueme, Sunday Eziechina, Helen Ignatius, Diana Marcus, Fisayomi Aderibigbe, James T. Koninga, Martin Meremikwu, Lina Moses, David W. Redding, Sagan Friant, David Safronetz, David Safronetz, David Safronetz, (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13218619.txt.
Description
David Simons and colleagues map Lassa fever exposure village by village in Nigeria in a 2026 serology study. Lassa virus causes serious disease in West Africa, and vaccine trials need places where exposure is high, yet community-level maps barely exist. Without them, trial planners risk choosing sites where the virus is nearly absent.
The team surveyed nine villages across Benue, Ebonyi, and Cross River states, recruiting 1,874 people and testing blood for Lassa antibodies with a specific assay. Overall modelled seroprevalence was 3.2 percent, but village estimates ranged from under one percent to six and a half percent, a sharp patchiness. Age patterns differed too: some villages showed the build-up of endemic exposure, others the signature of a recent outbreak among younger people. None of twenty-one risk factors, including eating rodents or farm work, consistently predicted infection. The authors conclude village-level surveys are indispensable before siting vaccine trials.
Catalog record
| CREATOR | David Simons, Christina Harden, Natalie Imirzian, Katharine E. T. Thompson, Nzube Michael Ifebueme, Sunday Eziechina, Helen Ignatius, Diana Marcus, Fisayomi Aderibigbe, James T. Koninga, Martin Meremikwu, Lina Moses, David W. Redding, Sagan Friant, David Safronetz, David Safronetz, David Safronetz, |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |